Alpha-Gal Syndrome Plasma

In Stock Samples

Lot Number Condition Volume Race/Ethnicity Age Gender Country of Collection Medications Vials Price Action
68262 Alpha-Gal Syndrome (AGS) 1.0 ML Caucasian 23 Female United States (US)
zoely birth control albuterol, PRN vitamin D supplement iron supplement
13 $316.00
66839 Alpha-Gal Syndrome (AGS) 1.0 ML Caucasian 34 Male United States (US)
Sertraline 50 mg QD Zyrtec 20 mg BID Epi Pen PRN Pepcid 20 mg BID Singulair 10 mg QD Ativan 0.5 mg PRN
12 $316.00
66675 Alpha-Gal Syndrome (AGS) 1.0 ML Caucasian 67 Male United States (US)
Klonidine 0.1 mg QD Valsartan/HCTZ 80/25 mg QD Atorvastatin 40 mg QD Metoprolol 100 mg QD
17 $316.00
66639 Alpha-Gal Syndrome (AGS) 1.0 ML Caucasian 55 Male United States (US)
B12/QOD Magnesium/QOD Zinc/QOD Potassium Citrate Vitamin C/QOD Lions mane/QOD
8 $316.00
66721 Alpha-Gal Syndrome (AGS) 1.0 ML Caucasian 44 Female United States (US) 12 $316.00

Alpha-Gal Syndrome Plasma | High-Quality Human Plasma from Alpha-Gal Syndrome (AGS) Donors

Alpha-Gal Syndrome Plasma is collected from donors clinically diagnosed with alpha-gal syndrome (AGS) and processed within hours of collection to preserve key analytes such as cytokines, proteins, and metabolites. This human plasma supports research focused on inflammatory pathways, immune profiling, and biomarker discovery in AGS pathophysiology.

Product Features

  • Research Use Only (RUO)
  • Plasma collected from clinically confirmed AGS donors
  • Processed within one day of collection
  • IRB-approved protocols and informed consent
  • Custom aliquot volumes available upon request

De-identified Donor Data

  • Verified alpha-gal syndrome (AGS) diagnosis
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Donor-reported medications, allergies, and comorbidities
  • Additional AGS-specific metadata available

Applications

  • Biomarker discovery and validation
  • Cytokine and inflammation profiling
  • Metabolomics and proteomics studies
  • Therapeutic response research

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
  • Documentation support available for regulatory review

Ordering and Customization

Alpha-Gal Syndrome plasma is available in standard and custom volumes. For international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations.

Protocols & Documentation

  • Plasma Isolation

    Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Plasma

Frequently Asked Questions

Showing 25–31 of 31 results

Do plasma samples come with clinical information (autoantibody status, HbA1c values, IHC results, stage information, genetic mutation data)?

1 Answer

YES – Comprehensive medical records are available and may contain information regarding autoantibody status.

YES – Sanguine offers both inventory for select conditions, as well as, prospective collection. For inventory visit https://sanguinebio.com/products/plasma/?pro_inventory=inventory.

We never thaw our plasma samples before shipping.

Our standard aliquot size for plasma is 1 mL but we have bulk plasma (50 to 150 mL) available for select conditions. https://sanguinebio.com/product/human-bulk-plasma/

YES – Sanguine bio provides “age-matched healthy controls” and longitudinal studies capabilities.

YES – custom age specifications available – The “Specify I/E Criteria” service allows you to define specific age ranges for donor selection.

Age ranges available – Donor metadata includes age specifications, and you can specify inclusion/exclusion criteria. For pediatric samples specifically, contact learnmore@sanguinebio.com.

1 2 3
×

Ask a Question

Need a custom Plasma cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information